Long-Term Follow-up of the West of Scotland Coronary Prevention Study

Cited by (416)

Items 301–400 of 416

1. Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease
   Chris J. Packard, Robin Young, Kevin Ross, Ian Ford, Baishali M. Ambegaonkar, Philippe Brudi, Colin McCowan · 2017 · European Heart Journal - Quality of Care and Clinical Outcomes
2. Evaluation of lipid services in the Republic of Ireland
   Ruth Agar, Meabh Prendergast, Vincent M. G. Maher · 2020 · Irish Journal of Medical Science (1971 -)
3. Electrical Plasticity and Cardioprotection in Myocardial Ischemia—Role of Selective Sodium Channel Blockers
   Rosalinda Madonna, Cihan Çevik, Maher Nasser · 2013 · Clinical Cardiology
4. Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011
   Katrin L. H. Walenta, Jan‐Malte Sinning, Christian M. Werner, Michael Böhm · 2011 · Clinical Research in Cardiology
5. Eosinophilic Esophagitis: Current Aspects of a Recently Recognized Disease
   Alfredo José Lucendo · 2010 · Gastroenterology Research
6. PRIMARY PREVENTION OF CARDIOVASCULAR COMPLICATIONS: VALUE OF STATINS
   S. Yu. Martsevich, Н. П. Кутишенко · 2009 · Rational Pharmacotherapy in Cardiology
7. Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving
   Michael David Shapiro · 2022 · Circulation
8. Cancer mortality according to lipid-lowering drugs and lipoproteins in a general population
   E. Bérard, Vanina Bongard, Jean Dallongeville, Dominique Arveiler, Jean‐Bernard Ruidavets, Jean Ferrières · 2011 · Current Medical Research and Opinion
9. Nonfatal Outcomes in the Primary Prevention of Atherosclerotic Cardiovascular Disease
   Matthew J. Czarny, Seth Shay Martin, Payal Kohli, Thomas Stephen Metkus, Roger Scott Blumenthal · 2014 · Circulation Cardiovascular Quality and Outcomes
10. Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits?
    Ishak A. Mansi, Jenny L. English, Michael J. Morris, Song Zhang, Eric M. Mortensen, Ethan A. Halm · 2017 · Journal of science and medicine in sport
11. Mechanisms of action of compounds that mimic beneficial effects of calorie restriction such as lifespan extension: Is taurine a promising candidate?
    Shoko Nishizono, Zi Wang, Yukari Watanabe, Yoshihisa Ohata, Takuya Chiba · 2017 · The Journal of Physical Fitness and Sports Medicine
12. Cardiovascular health in remote and rural communities
    Lara Bishop, Andy Ransom, Martin Laverty · 2018
13. Postponement of cardiovascular outcomes by statin use: A systematic review and meta‐analysis of randomized clinical trials
    Morten Hansen, Asbjørn Hróbjartsson, Anton Pottegård, Per Damkier, Kenneth Grønkjær Madsen, Manan Pareek, Morten Salling Olesen, Jesper Hallas · 2020 · Basic & Clinical Pharmacology & Toxicology
14. Bridging research gaps in geriatric oncology: unraveling the potential of pragmatic clinical trials
    Carlos Amir Carmona-Gonzalez, Mateus Trinconi Cunha, Ines B. Menjak · 2023 · Current Opinion in Supportive and Palliative Care
15. “Sufficient for the day is its own trouble”: Medicalizing Risk and the Way of Jesus
    Farr A. Curlin · 2023 · Christian bioethics Non-Ecumenical Studies in Medical Morality
16. LDL- Cholesterol and Outcome Prediction in Patients with Congestive Heart Failure
    Gideon Charach · 2014 · Journal of Cardiology & Current Research
17. Impact of compliance with antihypertensive and lipid-lowering treatment on cardiovascular risk Benefits of fixed-dose combinations
    Fotios Barkas, Moses Elisaf · 2013
18. Lipid-Modifying and Antiatherosclerotic Drugs
    Antonio M. Gotto, Lionel Henry Opie · 2009 · Elsevier eBooks
19. The Effect of Pravastatin on Insulin Resistance in Hyperglycemic Patients
    Yong Jin Jeong, Jung Min Kim, Seung Jae Jang, Jun Hee Bang, Young Gon Jung, Sung Taek Kim, Soon Hyoung Kang, Jong In Choi, Soo-sung Kim, Mi Yeon Kang · 2017 · Journal of Korean Diabetes
20. Statins Reduce Cardiovascular Events in Primary and Secondary Prevention Trials without Causing an Increase in Carcinoma
    Wilbert S. Aronow · 2009 · Journal of the American Geriatrics Society
21. Prescribing a Statin to a Cirrhotic Patient to Reduce Hepatic Decompensation and Improve Survival: Impossible You Say?
    James H. Lewis · 2014 · Digestive Diseases and Sciences
22. Statins, regulatory T cells, and pediatric graft coronary artery disease
    Mark R. Goldstein, Luca Mascitelli, Francesca Pezzetta · 2008 · Pediatric Transplantation
23. Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?
    Hallvard Holdaas · 2008 · European Heart Journal
24. Malignant Tumors of the Colon
    Jay Luther, Andrew Tan Chan · 2015 · Wiley eBooks
25. Is there Sufficient Enhancement of the Reduction in CVD Rates after a Decade of Statin Therapy to Justify Continuation?
    Jonathan E. Soverow, Karol E. Watson · 2014 · Current Atherosclerosis Reports
26. High-Risk Versus Population Prevention Strategies for NCDs: Geoffrey Rose Revisited in the Twenty-First Century
    John William Frank, Ruth Gillian Jepson · 2013 · Springer eBooks
27. Therapie von Fettstoffwechselstörungen
    Florian Custodis, Ulrich Laufs · 2014 · Herz
28. Evaluation of changes in serum lipid profile and fasting blood glucose levels in patients with gall stone disease before and after cholecystectomy
    Raj Kumar, Vikram Singh, Shabi Ahmad, Mayank Singh, Anshul Kumar Singh, Nandan Rai, Shirish Kumar, Abhinav Agarwal, Gaurav Kumar Mittal · 2020 · International Surgery Journal
29. Computed Tomography Imaging of Epicardial Adipose Tissue
    Bastian Balcer, Tienush Rassaf, Amir Abbas Mahabadi · 2020 · Contemporary cardiology
30. Lipid Disorders
    Michael T. McDermott · 2009 · Elsevier eBooks
31. EFFECT OF STATIN USE ON BIOCHEMICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY
    Mark R. Goldstein, Luca Mascitelli · 2011 · British Journal of Urology
32. Rethinking atherosclerotic cardiovascular disease prevention in the era of expanding therapies: could plaque stabilization reduce the need for lifelong treatments and polypharmacy?
    Kathrine Bruun, Martin Bødtker Mortensen · 2024 · Current Opinion in Cardiology
33. Should a statin be given to all hypertensive patients?
    Harry A.J. Struijker-Boudier · 2017 · Artery Research
34. The evidence on trial: cholesterol lowering and cancer: Table 1
    Andrew Maxwell Tonkin, Andrew Benjamin Forbes, S J Haas · 2009 · Heart Asia
35. Using Centrally Held Data to Validate Carotid Surgery Outcome Data
    Wesley P. Stuart, Keith Kelso Hussey, Ron K.G. Eifell, Robert J. Drummond, Ian Ford, GEORGE H. WELCH · 2013 · Stroke
36. The John Bryden memorial lecture: improving health with the community health index and developments in record linkage
    Frank Sullivan · 2014 · Journal of Innovation in Health Informatics
37. Telmisartan to Prevent Recurrent Stroke: The PRoFESS Study
    Gordon T. McInnes · 2008 · Stroke
38. Almost everyone over 50 should be put on a statin to reduce the risk of cardiovascular disease: A protagonist view.
    Pratik B. Sandesara, Douglas B. Bogart · 2013 · Europe PMC (PubMed Central)
39. ASSESSMENT OF FLOW MEDIATED DILATATION OF BRACHIAL ARTERY BY ANGIODEFENDER DEVICE AS COMPARED TO BRACHIAL ARTERY ULTRASOUND IMAGING.
    Mukesh Kumar Sharma, Chandra Bhanu Chandan, Abhishek Shukla, Deepak Ameta, Pradeep Kurmi · 2019 · International Journal of Medical and Biomedical Studies
40. Designing and Carrying Out Correlational Studies Using Real-World Data
    Charles P. Friedman, Jeremy C Wyatt, Joan S. Ash · 2022 · Health informatics
41. The Editor's Roundtable: JUPITER Follow-Up
    Vincent E. Friedewald, Christie Mitchell Ballantyne, Michael H. Davidson, Antonio M. Gotto, Paul M. Ridker, William Clifford Roberts · 2011 · The American Journal of Cardiology
42. Lifetime Risk Prediction in Cardiovascular Prevention: Wave of the Future?
    Steven E. Gryn, Daniel G. Hackam · 2012 · Canadian Journal of Cardiology
43. Primary prevention using statins: to be or not to be?
    Lars H. Breimer, Dimitri P. Mikhailidis · 2010 · Current Medical Research and Opinion
44. Low-density lipoprotein cholesterol and cardiovascular risk: a necessary causal agent but an insufficient predictor
    Gal Tsaban · 2021 · European Journal of Preventive Cardiology
45. Lipids and Cardiovascular Disease
    Malcolm Law · 2009
46. Prise en charge des patients dyslipidémiques : analyse des écarts entre le référentiel et la pratique dans un centre hospitalier
    Françoise Chiche, Philippe Giral, François Bourdillon, Éric Bruckert · 2008 · Annales d Endocrinologie
47. The Power of Diet in CVD Risk Factor Reduction
    Wendy M. Jenkins, Amy E. Jenkins, Alexandra L. Jenkins, Caroline Brydson · 2019 · Elsevier eBooks
48. Computed Tomography Coronary Angiography Is Feasible and Reliable for Proximal Coronary Segment Interpretation in Patients with Elevated Body Mass Index
    Anthony Salib, Michael Hay, Rahul G. Muthalaly, Timothy Abrahams, Nushrat Sultana, Raj Kanna, Ravi Rao, Akira Abe, John Bastwrous, Emma Aldous et al. · 2024 · Journal of Cardiovascular Development and Disease
49. Update on Investigation and Management of Dyslipidaemias and Cardiovascular Disease Risk
    Kofi Antwi, Ahai Luvai, Paul Downie, Ayoob Ghani, Megan Maple, Wycliffe Mbagaya · 2026 · British Journal of Hospital Medicine
50. FROM 'SICK MAN' TO 'LIVING LAB' – THE NARRATIVE OF SCOTTISH HEALTH SINCE DEVOLUTION
    Gill Haddow, James Mittra, Ken Snowden, Elisabeth Barlow, David Wield, Morris, Andrew · 2014 · Open Research Online (The Open University)
51. Another Telescope for Examining Statins: the SATURN Trial
    Rikesh Patel, ROBERT J. CHILTON · 2012 · Clinical Diabetes
52. Incidence of the Bertillon and Gompertz effects on the outcome of clinical trials
    Bertrand Marie Roehner · 2014 · Physica A Statistical Mechanics and its Applications
53. Review: Statins are effective for prevention of cardiovascular events in patients without coronary heart disease
    Finlay Aleck McAlister · 2009 · Annals of Internal Medicine
54. Gender Variation of Lipid Profiles of Type-2 Diabetes Mellitus Patients attended at a Specialized Diabetic Hospital in Dhaka
    R. Yeasmin, N. Nahar, M. Muttalib, M. N. H. Bhuiyan, A. Z. R. Zahid, Waseka Akhter Jahan · 2015 · Journal of Current and Advance Medical Research
55. Eff ects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
    Roosevelt Drive · 2013
56. Application of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline to the Korean National Health and Nutrition Examination Surveys from 1998 to 2012
    Young Shin Song, Tae Jung Oh, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang, Kyong Soo Park, Soo Kyung Lim · 2017 · Diabetes & Metabolism Journal
57. Safety and Effectiveness of Pravastatin in Korean Patients with Dyslipidemia Based on the Cardiovascular Risk Classification: Pooled Analysis of Four Observational Studies
    In‐Kyung Jeong, Hyuk‐Sang Kwon, Dae Jung Kim, Sin Gon Kim · 2025 · Endocrinology and Metabolism
58. Lipid disorders
    Emily B. Schroeder, Michael T. McDermott · 2013 · Elsevier eBooks
59. Treatment of cardiovascular risk factors in type 2 diabetes : time trends and clinical practice
    Eva Fhärm · 2010 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
60. Authors’ reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful
    David Preiss, Naveed A. Sattar · 2009 · Clinical Endocrinology
61. Industrial organization studies on pharmaceutical markets
    Tanja Saxell · 2014 · Työväentutkimus Vuosikirja
62. Investigating the impact of GIS modelled daily exposures to the retail food environment on routinely linked child health data
    Amy Mizen · 2018
63. Uncertainties in the Absence of Data: Use of Pravastatin in Young Children
    Anna Shifrin, Darshak M. Sanghavi · 2008 · The AMA Journal of Ethic
64. Are Statins Effective in High-Risk Primary Prevention?—Reply
    Kausik Kumar Ray, Sreenivasa Rao Kondapally Seshasai, J. Wouter Jukema, Naveed A. Sattar · 2010 · Archives of Internal Medicine
65. Power of the Pill : Views about Cardiovascular Risk and the Risk-reducing Effect of Statins
    Per Lytsy · 2011 · Socialmedicinsk tidskrift
66. Implementing Comparative Effectiveness Research in Primary Care
    Brady Bouchard, Hiran Shah · 2015
67. Primaire preventie van coronaire hartziekte. De West of Scotland Coronary Prevention Study (WOSCOPS): resultaten na 15 jaar follow-up
    E. M. van der Does · 2008 · Medisch-Farmaceutische Mededelingen
68. Long-Term Follow-Up of Cognitive Function and Activities of Daily Living in Older People: A Feasibility Study in the PROSPER Cohort
    Gillian D. Kerr · 2011 · The Open Clinical Trials Journal
69. Should we treat all primary prevention patients with statins?
    Robert M. Guthrie · 2008 · Current Atherosclerosis Reports
70. Stärken und Grenzen randomisierter Studien zur Lipidtherapie
    Eberhard E. T. Windler, Gerald Klose, Klaus Georg Parhofer, Elisabeth Steinhagen‐Thiessen · 2014 · CardioVasc
71. Simvastatin reduced major vascular events at 5 years in at-risk patients; benefits were maintained at 11 years
    Edward P. Havranek · 2012 · Annals of Internal Medicine
72. Optimizing lipid-lowering therapy in the prevention of coronary heart disease
    Chris J. Packard · 2010 · Expert Review of Clinical Pharmacology
73. The extra-pulmonary effects of chronic obstructive pulmonary disease (COPD)
    Michelle John · 2014 · Nottingham ePrints (University of Nottingham)
74. Using statins to treat ‘healthy’ patients: are we there yet?
    Bijal M. Shah, Robert Kemp, Michael B. Clearfield · 2009 · Expert Review of Pharmacoeconomics & Outcomes Research
75. Manejo terap?utico general y extrahospitalario del paciente con hiperlipidemia. Medidas generales y farmacol?gicas. Criterios cl?nicos y anal?ticos de seguimiento. Modificaciones posol?gicas y farmacol?gicas. Cumplimiento terap?utico
    T. Mantilla Morat · 2008 · Medicine - Programa de Formación Médica Continuada Acreditado
76. Prostate cancer, lipids, and statins
    Harumi Okuyama, Tomohito Hamazaki, Shinkan Tokudome · 2014 · European Journal of Lipid Science and Technology
77. Should statins be given routinely in all coronary patients?
    Lοukianos S. Rallidis, John P Lekakis, Dimitrios Th. Kremastinos · 2008 · International Journal of Cardiology
78. Dyslipidemia among People with Diabetes: Control and Pattern of Prescribing
    Jameel Nasser · 2011
79. For peer review only Methodology of a large streamlined safety study: protocol of the Standard care versus Celecoxib Outcome Trial (SCOT trial)
    Thomas MacLennan MacDonald, Ian Ford · 2012
80. Therapeutic Class Overview HMG CoA Reductase Inhibitors
    Lescol Xl · 2012
81. POLICY FORUM Uncertainties in the Absence of Data: Use of Pravastatin in Young Children
    Anna Shifrin, Darshak M. Sanghavi · 2008
82. Invited review Morbidity and mortality trials: black and white or shades of grey?
    Gordon T. McInnes · 2009
83. Treating elevated LDL cholesterol in patients with low short-term risk: Decision making at the limits of EBM
    Mark J. Pletcher · 2015 · BMJ Evidence-Based Medicine
84. Cardiovascular Benefits of Aggressive Cholesterol-Lowering Therapy
    Michael B. Clearfield · 2011 · The Journal of the American Osteopathic Association
85. Long-Term Follow-Up of a Landmark Statin Trial
    Allan S. Brett · 2007 · Journal watch
86. Long term follow up of the early repolarization pattern in participants in the West of Scotland Coronary Prevention study
    Elaine Clark, Ian Ford, Peter W. Macfarlane · 2015 · Computing in cardiology
87. Impact de la prise de statines sur les groupes à risques de progression de D'Amico et la survie sans récidive biologique après prostatectomie totale Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?
    Vincent Misraï, Benjamin A. Elman, I. Latorzeff, D. Portalez, Pascale Grosclaude · 2012
88. Prostate brachytherapy: the impact of smoking on recurrence and overall survival of localized prostate cancer
    Edwin Cohen, Justin Robinson, Paul Margolis, Marcia Gaut, Amie Alperson, Amie Alperson, Mary Feagin · 2013 · American Journal of BioMedicine
89. The West of Scotland Coronary Prevention Study: Long-Term Results
    Harlan M. Krumholz, Sm · 2007 · Journal watch
90. A real options game approach to health technology assessment
    Edit Remák · 2015 · Brunel University Research Archive (BURA) (Brunel University London)
91. PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Statins and Colorectal Cancer
    Paul J. Lochhead, Andrew Tan Chan · 2013
92. "Statins, which are prescribed to millions of patients for hypercholesterolemia treatment, have additional pleiotropic effects beyond cholesterol reduction that may include anticancer properties."
    Fotios Barkas, James J. DiNicolantonio, Evangelos N. Liberopoulos · 2013
93. New onset heart failure: origin and manifestation
    Franciscus Paulus Johannes Brouwers · 2014 · University of Groningen research database (University of Groningen / Centre for Information Technology)
94. Pravastatin: A First Generation HMG CoA Reductase Inhibitor ☆
    Jerry W. Reagan · 2018 · Elsevier eBooks
95. Pattern of Non-Adherence to Statins in Patients of Dominican Descent in an Outpatient Setting
    E. Kosmas Constantine, Rosmery Morcelo, Martinez Ian, R. Velez Edwards Digna, Hernandez Nolberto, D. Montan Peter, Guzman Eliscer · 2017 · Enliven Clinical Cardiology and Research
96. Una historia resumida. Impacto de los avances en el control lipídico
    Fernando Sabatel-Pérez, Joaquín Sánchez-Prieto Castillo, Luis Rodrı́guez Padial · 2017 · Revista Española de Cardiología Suplementos
97. Unjustified discontinuation of statin preventive therapy - clinical consequences
    Milan Kriška, Jana Tisoňová, Monika Laššánová, Andrej Dukát · 2018 · Klinická farmakologie a farmacie
98. The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal
    Cancer Sehdev · 2015
99. Dislipidemias: terapêutica atual e perspectivas futuras na redução de riscos cardiovasculares
    Marcelo Gustavo Lopes, Andrei Carvalho Sposito · 2018 · Revista Paulista de Reumatologia
100. Current World Literature
     2008 · Current Opinion in Endocrinology Diabetes and Obesity